GO
Loading...

Enter multiple symbols separated by commas

Merck & Co Inc

More

  • Merck& Co.' s second-quarter profit plunged by two-thirds, hammered by the sale of its consumer business, unfavorable currency exchange rates, lower sales of some key drugs and hefty one-time charges. The world's fifth-biggest drugmaker by revenue beat modest Wall Street expectations and raised its full-year profit forecast by a dime per share, but shares...

  • Minefield for market with Fed, earnings, commodities Monday, 27 Jul 2015 | 8:08 AM ET
    An oil trader works on the floor of the New York Mercantile Exchange.

    The Fed meets next week, but a commodities meltdown and earnings season are adding to concerns about global growth and may steal some of its thunder.

  • What to expect from Merck & Pfizer tomorrow Monday, 27 Jul 2015 | 6:52 AM ET
    What to expect from Merck & Pfizer tomorrow

    CNBC's Dominic Chu reports on Kensho studies, looking at Merck and Pfizer's stock performances around quarterly reports.

  • Allergan buys Naurex for $560M as deal talk swirls Sunday, 26 Jul 2015 | 11:20 AM ET
    A clinical technician holds a syringe and a vial of Allergan Botox, produced by Allergan.

    Allergan is considering a breakup of the company into two businesses, a person familiar with the matter told Reuters on Friday.

  • TRENTON, N.J.— An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options— all much more effective but extremely costly— for patients with the liver-destroying virus. Daklinza, developed by New York- based Bristol-Myers Squibb Co., is the first drug approved to...

  • Buy the dip? Here's the bullish case now Friday, 24 Jul 2015 | 1:53 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Two Strategists favor U.S. stocks vs. global stocks

  • Health care takes earnings hot hand into week ahead Friday, 24 Jul 2015 | 10:23 AM ET
    Pfizer headquarters in New York.

    Health-care stocks are batting 12 for 12 in beating earnings estimates. Will the streak last?

  • Roche CEO warns on high pharma valuations Thursday, 23 Jul 2015 | 6:26 AM ET

    Valuation are "very high" in the pharmaceutical sector, Roche CEO Severin Schwan told CNBC on Thursday after the company posted a rise in sales.

  • July 20- Bristol-Myers Squibb Co said a late-stage trial of its drug, Opdivo, was stopped early after the immunotherapy was found to be effective in patients with the most common form of kidney cancer. The drug competes with Merck& Co's Keytruda. AstraZeneca Plc, Pfizer Inc and other drugmakers are also developing PD-1 inhibitors, or similar drugs known as PD-L1...

  • Cramer: Don't abandon finance & tech stocks, yet Thursday, 16 Jul 2015 | 6:12 PM ET
    Bank of America

    Jim Cramer says don't give up on the banks & tech stocks yet! Sometimes there is more than one way to skin a cat.

  • Stocks close up more than 1% amid Greece relief Monday, 13 Jul 2015 | 4:00 PM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks closed more than 1 percent higher, following gains overseas on news of a bailout agreement between Greece and its creditors.

  • Early movers: MRK, TSLA, FIT, SHAK, NKE & more Tuesday, 7 Jul 2015 | 7:49 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Trader on the floor of the New York Stock Exchange.

    U.S. stocks ended little changed as investors eyed the jobs report and were on edge ahead of Greece's Sunday referendum.

  • Two big problems with generic-drug substitution Tuesday, 23 Jun 2015 | 3:54 PM ET
    Pharmaceutical drugs

    Automatic generic-drug substitution poses several big problems, says NYU Professor Melissa Schilling.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed higher, following a global rally in equities, as investors cheered signs of progress in the Greece debt negotiations.

  • NEW YORK, June 17- Merck& Co Inc has agreed to pay $5.9 million to resolve claims that a former unit fraudulently promoted a drug used to treat pink eye for unapproved purposes, U.S. authorities announced on Wednesday. Attorney Preet Bharara said Inspire Pharmaceuticals, which Merck acquired in 2011 and later sold, promoted its drug AzaSite to healthcare...

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks traded lower as uncertainty over Greece weighed on sentiment and investors kept an eye on bond yields ahead of next week's FOMC meeting.

  • Cramer: Massive biotech moves that make sense Thursday, 11 Jun 2015 | 6:57 PM ET
    A worker prepares a flow cell slide for a genetic sequencing machine at a Regeneron Pharmaceuticals laboratory company's headquarters in Tarrytown, New York.

    Jim Cramer discusses the huge moves that the biotech stocks have made recently—do these moves make sense for your portfolio?

  • June 8- Details of a large heart safety study presented on Monday appear to give Merck and Co's diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales growth for the drugmaker's biggest product. Januvia, an oral medication known chemically as sitagliptin that helps lower blood sugar levels, had sales of about $4 billion in...

  • June 4- A bipartisan group of U.S. lawmakers introduced legislation on Thursday to boost protections for pregnant workers in response to a recent U.S. Supreme Court ruling that revived discrimination claims by a former United Parcel Service Inc driver. The group of lawmakers backing the bill includes Senator Kelly Ayotte, a Republican from New Hampshire, but...